UpdatesPress Release

Cipla's US subsidiary partners with Qilu for exclusive licensing & supply of a Keytruda biosimilar (QL2107) in the US market.

Cipla Limited logo
Cipla LimitedCIPLA · Filed with the exchange

This strategic move aims to expand Cipla's oncology portfolio and improve access to affordable biologics.

Read the original filing(PDF)

No comments yet. Be the first.

More from Cipla Limited

All announcements